SEC Form 4 · accession 0001209191-18-001011
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francois Lebel
Officer — Executive Vice President R&D
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 4:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 29, 2017 | A | 116,000 | $0.00 | A | 253,683 | D | |
| Common StockF2 | Dec 30, 2017 | F | 31,450 | $4.14 | D | 222,233 | D | |
| Common StockF2 | Dec 31, 2017 | F | 21,667 | $4.14 | D | 200,566 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F138,666 shares shall vest on 12/29/2018; 38,667 shares shall vest on each of 12/29/2019 and 12/29/2020.
- F2Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.